Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Chosa Oncology

0.825

 

SEK

Less than 1K followers

CHOSA

Spotlight Stock Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Ownership
Investor consensus
Compare
+3.12%
+21.32%
+18.19%
-1.55%
+21.32%
-22.17%
-97.67%
-93.22%
-93.87%

Chosa Oncology, Danish -Swedish biotechnology company, has developed the iCIP platform, which includes a liposomal formulation of cisplatin (LiPlaCis) and the companion diagnostic (DRP) tool detecting patients who benefits the most of the cisplatin treatment. The recently achieved clinical phase 2b results mean that the Company is now gearing up the business development activities to find partners for partnership or trade deal.

Read more
Market cap
58.53M SEK
Turnover
-
Revenue
-
EBIT %
-
P/E
-
Dividend yield-%
-
Financial calendar
30/5
2025

Interim report Q1'25

13/6
2025

General meeting '25

29/8
2025

Interim report Q2'25

All
Press releases
ShowingAll content types
Regulatory press release5/13/2025, 12:48 PM

Kallelse till årsstämma i Chosa Oncology AB

Chosa Oncology
Regulatory press release5/13/2025, 12:48 PM

Notice of annual general meeting in Chosa Oncology AB

Chosa Oncology
Regulatory press release5/9/2025, 1:44 PM

Chosa Oncology AB: CHOSA- Extending CHOSA's Platin DRP: Predicting Carboplatin Efficacy in Breast Cancer

Chosa Oncology

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/9/2025, 1:44 PM

Chosa Oncology AB: CHOSA -CHOSAs Platin DRP utökas: Förutsäger också effekt av carboplatin vid bröstcancer

Chosa Oncology
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.